Streetbeat News

Products Services

CHPT

EVGO

TSLA

Tesla, Inc. (TSLA) has significantly outpaced competitors ChargePoint Holdings, Inc. (CHPT) and EVgo Inc (EVGO) in the installation of fast chargers, adding 6,000 in 2023 while CHPT and EVGO added only 410 and 850, respectively. Tesla's unique connector design gives it a competitive edge. ChargePoint experienced a market value decline and a CEO change, with new CEO Rick Wilmer citing economic uncertainty as a reason for customers' reluctance to invest in chargers. U.S. public charging stations are behind BloombergNEF's 2023 forecast by 76%, and the U.S. is expected to trail China and Europe in charging infrastructure. CHPT and EVGO stocks are trading lower premarket, as is TSLA.

Portfolio Pulse from Nabaparna Bhattacharya

January 09, 2024 | 12:33 pm

HYZN

Hyzon Motors Inc. (NASDAQ:HYZN) has made significant progress in 2023, deploying 19 hydrogen fuel cell electric vehicles (FCEVs) across three continents and advancing its 200kW fuel cell system technology. The company met its annual guidance by delivering vehicles to customers in the U.S., Europe, and Australia, including the first heavy-duty fuel cell electric truck in the U.S. Hyzon's single-stack 200kW fuel cell system, which is lighter and more cost-effective than combining two 100kW systems, has completed B-sample development. The company is now entering the C-sample development phase, with production expected to start in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:33 pm

ASTI

Ascent Solar Technologies, Inc. (ASTI) has signed a letter of intent to supply yearly solar array orders to an undisclosed private company, with deliveries starting in 2027. This agreement could potentially increase ASTI's future revenues and strengthen its position in the solar energy market.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:30 pm

GSK

GSK plc has acquired Aiolos Bio Inc. for $1 billion with an additional $400 million in potential milestone payments. The deal gives GSK access to AIO-001, a monoclonal antibody for asthma treatment, ready for phase 2 trials. AIO-001, licensed from Jiangsu Hengrui Pharmaceuticals, could expand GSK's respiratory portfolio, targeting a broader asthma patient base. GSK's focus on respiratory diseases is part of its strategy to offset upcoming patent expirations. In 2022, respiratory products generated £11 billion for GSK. GSK shares rose 0.30% in premarket trading.

Portfolio Pulse from Vandana Singh

January 09, 2024 | 12:26 pm

GOEV

MBLY

RENT

The article highlights three consumer discretionary stocks considered oversold based on their Relative Strength Index (RSI) values, suggesting a potential buying opportunity. Canoo Inc. (GOEV) recently purchased manufacturing assets and saw a slight stock decline, with an RSI of 29.65. Rent the Runway, Inc. (RENT) reported disappointing revenue results, leading to a 30% stock drop over the past month and an RSI of 26.16. Mobileye Global Inc. (MBLY) announced significant production design wins, yet its stock fell 26% in the past five days, with an RSI of 19.38.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 12:22 pm

QCOM

Asus has introduced the ROG Phone 8 series at CES 2024, featuring Qualcomm's Snapdragon 8 Gen 3 chipset. The new lineup includes the ROG Phone 8, ROG Phone 8 Pro, and ROG Phone 8 Pro Edition, with improved design, AI features, and enhanced cooling systems. The phones are priced from $1,099 to $1,499 and are aimed at both gamers and a broader audience due to design improvements. A U.S. release date is pending.

Portfolio Pulse from Rounak Jain

January 09, 2024 | 12:22 pm

CEVA

Ceva, Inc. has announced a partnership with THX Ltd. to integrate premium spatial audio into hearables, consumer, and mobile products. This collaboration aims to enhance the audio experience by leveraging Ceva's signal processing expertise and THX's renowned audio standards.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:18 pm

TNXP

Tonix Pharmaceuticals presented additional safety and tolerability data from the RESILIENT Phase 3 study of TNX-102 SL for fibromyalgia management at Biotech Showcase 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:17 pm

NUWE

Nuwellis has been granted a U.S. patent (#11865302) for an extracorporeal blood filtering machine and methods. This patent could potentially enhance the company's product portfolio and provide a competitive edge in the medical device market. The patent grant may also open up new opportunities for partnerships or licensing agreements, and it could serve as a barrier to entry for competitors.

Portfolio Pulse from Charles Gross

January 09, 2024 | 12:14 pm

MCRB

Seres Therapeutics has been granted FDA Fast Track designation for SER-155, a microbiome therapeutic aimed at preventing gastrointestinal-associated bacterial infections. The Phase 1b placebo-controlled Cohort 2 data for SER-155 is expected to be released in the third quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:14 pm